NL1026203C2 - Verbindingen toepasbaar voor de behandeling van ziekten. - Google Patents

Verbindingen toepasbaar voor de behandeling van ziekten. Download PDF

Info

Publication number
NL1026203C2
NL1026203C2 NL1026203A NL1026203A NL1026203C2 NL 1026203 C2 NL1026203 C2 NL 1026203C2 NL 1026203 A NL1026203 A NL 1026203A NL 1026203 A NL1026203 A NL 1026203A NL 1026203 C2 NL1026203 C2 NL 1026203C2
Authority
NL
Netherlands
Prior art keywords
phenyl
hydroxy
propyl
hydroxymethyl
amino
Prior art date
Application number
NL1026203A
Other languages
English (en)
Dutch (nl)
Other versions
NL1026203A1 (nl
Inventor
Paul Alan Glossop
Charlotte Alice Louise Lane
Russell Andrew Lewthwaite
Mark Edward Bunnage
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NL1026203A1 publication Critical patent/NL1026203A1/nl
Application granted granted Critical
Publication of NL1026203C2 publication Critical patent/NL1026203C2/nl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/14Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46Y being a hydrogen or a carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40Acylated substituent nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Indole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
NL1026203A 2003-05-15 2004-05-14 Verbindingen toepasbaar voor de behandeling van ziekten. NL1026203C2 (nl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP03010944 2003-05-15
EP03010944A EP1477167A1 (en) 2003-05-15 2003-05-15 [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists
GB0329874 2003-12-23
GBGB0329874.2A GB0329874D0 (en) 2003-05-15 2003-12-23 Compounds useful for the treatment of diseases

Publications (2)

Publication Number Publication Date
NL1026203A1 NL1026203A1 (nl) 2004-11-16
NL1026203C2 true NL1026203C2 (nl) 2005-07-26

Family

ID=33454327

Family Applications (1)

Application Number Title Priority Date Filing Date
NL1026203A NL1026203C2 (nl) 2003-05-15 2004-05-14 Verbindingen toepasbaar voor de behandeling van ziekten.

Country Status (29)

Country Link
EP (2) EP1477167A1 (ko)
JP (1) JP3966897B2 (ko)
KR (1) KR100749990B1 (ko)
CN (1) CN1791407A (ko)
AP (1) AP2005003443A0 (ko)
AR (1) AR044335A1 (ko)
AT (1) ATE413879T1 (ko)
AU (1) AU2004237952A1 (ko)
BR (1) BRPI0410391A (ko)
CA (1) CA2525006A1 (ko)
CL (1) CL2004000963A1 (ko)
CO (1) CO5700776A2 (ko)
DE (1) DE602004017710D1 (ko)
DK (1) DK1624868T3 (ko)
EA (1) EA200501615A1 (ko)
EC (1) ECSP056164A (ko)
ES (1) ES2314395T3 (ko)
GB (1) GB0329874D0 (ko)
IS (1) IS8080A (ko)
MA (1) MA27840A1 (ko)
MX (1) MXPA05012329A (ko)
NL (1) NL1026203C2 (ko)
NO (1) NO20055854L (ko)
OA (1) OA13165A (ko)
PA (1) PA8603001A1 (ko)
PE (1) PE20060095A1 (ko)
TW (1) TW200505865A (ko)
UY (1) UY28317A1 (ko)
WO (1) WO2004100950A1 (ko)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50538B (sr) * 2004-01-22 2010-05-07 Pfizer Limited Sulfonamidni derivati namenjeni lečenju bolesti
ATE375977T1 (de) 2004-01-22 2007-11-15 Pfizer Sulfonamidderivate zur behandlung von krankheiten
AU2005223488A1 (en) * 2004-03-17 2005-09-29 Pfizer Inc. Phenylethanolamine derivatives as Beta-2 agonists
CA2560368A1 (en) * 2004-03-23 2005-10-06 Pfizer Inc. Compounds for the treatment of diseases
WO2005092860A1 (en) * 2004-03-23 2005-10-06 Pfizer Limited Compounds for the treatment of diseases
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
EP1924553A1 (en) 2005-08-08 2008-05-28 Argenta Discovery Limited Bicyclo[2.2.]hept-7-ylamine derivatives and their uses
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
CA2667962A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
KR20100113557A (ko) 2008-01-11 2010-10-21 노파르티스 아게 키나제 억제제로서의 피리미딘
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
PT2379507E (pt) 2008-12-30 2014-01-21 Pulmagen Therapeutics Inflammation Ltd Compostos de sulfonamida para o tratamento de desordens respiratórias
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US9102671B2 (en) 2011-02-25 2015-08-11 Novartis Ag Compounds and compositions as TRK inhibitors
GB201601301D0 (en) * 2016-01-25 2016-03-09 Takeda Pharmaceutical Novel compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8528633D0 (en) * 1985-11-21 1985-12-24 Beecham Group Plc Compounds
US5629200A (en) * 1993-11-18 1997-05-13 Daicel Chemical Industries, Ltd. Production of optically active 2-amino-1-phenylethanol derivatives by asymetrical assimilation
US5561142A (en) * 1994-04-26 1996-10-01 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
JPH11504649A (ja) * 1995-05-10 1999-04-27 ファイザー・インコーポレーテッド β−アドレナリン作働性アゴニスト
US6090942A (en) * 1998-10-15 2000-07-18 Pfizer Inc. Process and intermediates for a β3 -adrenergic receptor agonist

Also Published As

Publication number Publication date
NO20055854L (no) 2006-02-10
UY28317A1 (es) 2004-12-31
NL1026203A1 (nl) 2004-11-16
OA13165A (en) 2006-12-13
KR20060017607A (ko) 2006-02-24
ECSP056164A (es) 2006-04-19
ES2314395T3 (es) 2009-03-16
JP2007503458A (ja) 2007-02-22
CA2525006A1 (en) 2004-11-25
IS8080A (is) 2005-10-20
WO2004100950A1 (en) 2004-11-25
DK1624868T3 (da) 2009-02-23
AU2004237952A1 (en) 2004-11-25
CO5700776A2 (es) 2006-11-30
CN1791407A (zh) 2006-06-21
DE602004017710D1 (de) 2008-12-24
JP3966897B2 (ja) 2007-08-29
AR044335A1 (es) 2005-09-07
EP1624868B1 (en) 2008-11-12
ATE413879T1 (de) 2008-11-15
PE20060095A1 (es) 2006-02-18
TW200505865A (en) 2005-02-16
AP2005003443A0 (en) 2005-12-31
EP1477167A1 (en) 2004-11-17
MA27840A1 (fr) 2006-04-03
KR100749990B1 (ko) 2007-08-16
EP1624868A1 (en) 2006-02-15
EA200501615A1 (ru) 2006-06-30
PA8603001A1 (es) 2004-12-16
MXPA05012329A (es) 2006-01-30
GB0329874D0 (en) 2004-01-28
BRPI0410391A (pt) 2006-07-18
EP1624868B9 (en) 2009-08-12
CL2004000963A1 (es) 2005-03-18

Similar Documents

Publication Publication Date Title
NL1026203C2 (nl) Verbindingen toepasbaar voor de behandeling van ziekten.
US7268147B2 (en) Compounds useful for the treatment of diseases
NL1026329C2 (nl) 2-Amino-pyridinederivaten toepasbaar voor de behandeling van ziekten.
US7547731B2 (en) Formamide derivatives for the treatment of diseases
US7482487B2 (en) Phenylaminoethanol derivatives as β2 receptor agonists
NL1028599C2 (nl) Verbindingen voor de behandeling van ziekten.
NL1028087C2 (nl) Sulfonamiderivaten voor de behandeling van ziekten.
EA009735B1 (ru) Сульфонамидные производные для лечения заболеваний
WO2005092861A1 (en) Quinolinone derivatives pharmaceutical compositions containing them and their use
JP4054366B2 (ja) 疾患の治療のために有用な化合物
EP1577291A1 (en) Phenylethanolamine derivatives as beta-2 agonists
US20090076152A1 (en) Novel Compounds Active as Muscarinic Receptor Antagonists
US7375100B2 (en) 2-amino-pyridine derivatives useful for the treatment of diseases
US7629358B2 (en) Compounds useful for the treatment of diseases
NL1028597C2 (nl) Formamidederivaten voor de behandeling van ziekten.
NL1028559C2 (nl) Verbindingen die bruikbaar zijn voor de behandeling van ziekten
UA79379C2 (en) (2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethylaminopropylphenyl derivatives as beta 2 agonists
MXPA06010629A (en) Phenylaminoethanol derivates as beta2 receptor agonists

Legal Events

Date Code Title Description
AD1A A request for search or an international type search has been filed
RD2N Patents in respect of which a decision has been taken or a report has been made (novelty report)

Effective date: 20050323

PD2B A search report has been drawn up